Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibit... (ates the abilities andexpertise in Amira...)

Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program

Date:2/4/2008

ates the abilities and expertise in Amira to expedite the delivery of novel medicines. We are particularly pleased to have partnered with GSK, one of the leading pharmaceutical companies in the world, and a company that has a strong heritage in the treatment of respiratory diseases."

About respiratory diseases

The prevalence of asthma is increasing globally and despite the success of inhaled beta-agonist and corticosteroid therapy there is still a significant need for alternative therapies. Although other therapies are available that target the leukotriene pathway, a FLAP inhibitor has the potential to inhibit a broad spectrum of leukotrienes. FLAP inhibitors are also being investigated for use in other respiratory indications, including rhinitis, as well as having potential for the treatment of other inflammatory and cardiovascular diseases.

The global non-steroidal market for the treatment of asthma and rhinitis is currently worth in excess of US $4 billion; prescriptions for the treatment of rhinitis contribute 15% to total worldwide sales of non-steroidals. A FLAP inhibitor with improved efficacy and equal or improved safety and tolerability to existing leukotriene receptor antagonists, in both asthma and rhinitis, would likely capture a significant portion of this market.

About the agreement

Commenting on the agreement, Dave Allen, SVP Respiratory Centre of Excellence in Drug Discovery, GlaxoSmithKline said: "The role of anti-leukotriene agents has been well validated in the treatment of respiratory diseases. We are very excited at entering into this global agreement with Amira to deliver novel therapies to patients based on this mechanism."

In addition Moncef Slaoui, Chairman R&D, GSK said: "As leaders in the development, manufacture and marketing of medicines for respiratory diseases GSK is pleased to be introducing this treatment to our product pipeline. We believe AM103, a novel FLAP inhibitor, has the potential to
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Amira Pharmaceuticals Appoints First Vice President of Development
2. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
3. Poniard Pharmaceuticals Announces Upcoming Conference Participation
4. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
5. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
6. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
7. Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
8. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
9. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

Post Your Comments:

(Date:5/21/2013)... Diehard soccer fans will definitely want to see a ... between Manchester City and Chelsea FC at Busch ... teams are highly decorated in the English Premiere League of ... Busch Stadium, home of the St. Louis Cardinals, a professional ... a professional sporting event and non-baseball game will be held ...

(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay ... life, but some of the changes brought about by ... diabetes. New research has found that people with ... percent higher risk of having a severe low blood ... compared to people with diabetes who aren,t depressed. ...

(Date:5/21/2013)... Philosophical Society (APS) has awarded New York University neuroscientist ... in recognition of his "pioneering work on the neuroscience ... University,s Center for Neural Science, is the second NYU ... yearsJoseph LeDoux received the honor in 2011 in recognition ... emotional learning, particularly fear learning, and fear memory." ...

(Date:5/21/2013)... Representatives with Hammerhead Bicycles announced today that their re-launched bike ... achieved its overall goal of becoming a standalone brand. , ... Bicycles from a house brand to a standalone bike brand,” ... that the bike shop will go forward as Switchback ... 29er and 650b. , “The bike shop will ...

(Date:5/21/2013)... major Ohio universities and four hospitals have joined with ... collaborative research program aimed exclusively at finding the unknown ... to invest $10 million in the program over five ... Center -- Ohio Collaborative is a unique research enterprise," ... of Dimes. "This new transdisciplinary, team-based research model will ...

Breaking Medicine News(10 mins):Health News:Manchester City vs. Chelsea FC Tickets: Cheap Concert Tickets has Slashed Prices on Manchester City vs. Chelsea FC Tickets at Busch Stadium in St. Louis, MO 2 Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2 Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3 Health News:NYU's Movshon receives Lashley Award for his research on the neuroscience of vision 2 Health News:Hammerhead Bicycles Now a Standalone Brand 2 Health News:New multi-million dollar research center aims to solve the mystery of premature birth 2 Health News:New multi-million dollar research center aims to solve the mystery of premature birth 3

[0] Manchester City vs. Chelsea FC Tickets: Cheap Concert Tickets has Slashed Prices on Manchester City vs. Chelsea FC Tickets at Busch Stadium in St. Louis, MO [0] Depression May Raise Low Blood Sugar Risk in Diabetics [0] NYU's Movshon receives Lashley Award for his research on the neuroscience of vision [0] Hammerhead Bicycles Now a Standalone Brand [0] New multi-million dollar research center aims to solve the mystery of premature birth

... Tanaka, president and CEO of Menicon Co., Ltd. ... was appointed as Singapore,s Honorary Consul-General in Nagoya, ... Singapore. The appointment was effective April 20, 2009. ... corporate headquarters in Nagoya.(Photo: http://www.newscom.com/cgi-bin/prnh/20090508/PR34572 ...

... OAK BROOK, Ill., May 7 The University HealthSystem ... 3-year agreement to one supplier, Sodexo Inc., based in ... which has 2 optional 1-year renewal periods, became effective ... of comprehensive management solutions for food and nutrition services ...

... Congress to Make Health Reform Work for ChildrenSTANFORD, Calif., ... Stanford is joining the National Association of Children,s ... grassroots mobilization campaign asking Congress and the Obama Administration ... "Our hospital is extraordinarily proud to be taking ...

... 7 MedQuist Inc., (Nasdaq: MEDQ ) a ... technology-enabled clinical documentation workflow, today announced its unaudited operating results ... the first quarter of 2009 was $6.9 million, an increase ... a loss of $4.4 million was reported. Earnings per share ...

... 7 Trey Anastasio, lead singer of the rock band ... Wednesday, May 6, to participate in a day-long celebration marking ... National Association of Drug Court Professionals (NADCP) in calling for ... Mr. Anastasio recognized over fifteen members of Congress for their ...

... statement from Georges C. Benjamin, MD, FACP, FACEP (E), ... Public Health Association (APHA) joins other leading health organizations ... Obama,s FY 2010 budget."Of particular note is the $635 ... to finance health reform and ensure that we all ...

Dr. Tanaka Appointed as Honorary Consul-General by Republic of Singapore University HealthSystem Consortium Selects Sodexo to Provide Food and Nutrition Services Lucile Packard Children's Hospital at Stanford to Raise Its Voice for Kids in Health Care Reform Debate MedQuist Reports First Quarter 2009 Results Phish Frontman Trey Anastasio Visits Capitol Hill to Support Drug Courts and Calls on Congress to Put a Drug Court Within Reach of Every American in Need APHA Applauds Health Reform Fund and Other Health Investments in Budget

(Date:5/21/2013)... Mass. , May 21, 2013 /PRNewswire/ ... research and advisory firms for pharmaceutical and ... an emerging agent on key efficacy endpoints, ... progression, has the most influence over surveyed ... advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast cancer. ...

(Date:5/21/2013)... , May 21, 2013 Hurel Corporation ("Hurel"), ... microfluidic cell-based assay platforms, today announced the appointment of ... to the Company,s Board of Directors. Dr. MacDonald is ... the Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical ... by Merck & Co. in 2009. Over ...

(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue: ... Coherence Tomography (OCT) http://www.reportlinker.com/p01187977/Global-Markets-and-Technologies-for-Optical-Coherence-Tomography-OCT.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ... BCC,s aim ... synopsis of the current and future characteristics ...

[0] Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer [0] Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors [0] Global Markets and Technologies for Optical Coherence Tomography (OCT)

... May 5 Reportlinker.com announces that a new market research report is available in its catalogue: , ... Market , , , ... This Kalorama Information report - The World Anesthesia Drug Market - focuses on three primary segments of ... General Anesthesia , , , ...

... ,, SHENZHEN, China , ... Inc.,(Nasdaq: WWIN ; "Winner Medical" or the "Company"), ... PurCotton(R) materials,for the medical and consumer products industries, today ... quarter of fiscal year 2010 on, Tuesday, May 11 ...

Cached Medicine Technology:Reportlinker Adds The World Anesthesia Drug Market 2 Reportlinker Adds The World Anesthesia Drug Market 3 Reportlinker Adds The World Anesthesia Drug Market 4 Reportlinker Adds The World Anesthesia Drug Market 5 Reportlinker Adds The World Anesthesia Drug Market 6 Reportlinker Adds The World Anesthesia Drug Market 7 Reportlinker Adds The World Anesthesia Drug Market 8 Reportlinker Adds The World Anesthesia Drug Market 9 Reportlinker Adds The World Anesthesia Drug Market 10 Winner Medical Group Inc. to Host Second Quarter Fiscal Year 2010 Earnings Conference Call on Tuesday, May 11, 2010 at 5:00 p.m. EDT 2 Winner Medical Group Inc. to Host Second Quarter Fiscal Year 2010 Earnings Conference Call on Tuesday, May 11, 2010 at 5:00 p.m. EDT 3 Winner Medical Group Inc. to Host Second Quarter Fiscal Year 2010 Earnings Conference Call on Tuesday, May 11, 2010 at 5:00 p.m. EDT 4

Reportlinker Adds The World Anesthesia Drug Market Winner Medical Group Inc. to Host Second Quarter Fiscal Year 2010 Earnings Conference Call on Tuesday, May 11, 2010 at 5:00 p.m. EDT

Reusable Components Compatible with VERSASTEP™ Reposable Access System....

The VersaStep™ 5 mm and VersaStep™ PLUS Reposable system components for creating each access port are supplied in separate packages....

... VERSASTEP™ Plus Long Instrument for ... ,The VERSASTEP™ Plus Long Instrument ... a unique endoscopic entry device ... procedures. It is used to ...

... Step™ and Mini Step™ device components are supplied ... Single Use System is supplied sterile in 2/3, ... in various configurations and combinations. They are used ... needle and the Step™ radially Expandable Sleeve. The ...

Medicine Products:

Reusable Components VersaStep™ Reposable Powershield™ (Reusable Radiolucent Cannulae - Short Length)VersaStep™ Plus Long Instrument with 150 mm Working Length STEP™ Short Instruments